{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:01:52Z","timestamp":1789909312598,"version":"4.0.1"},"reference-count":16,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We reviewed data for almost 300,000 clinical\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            urinary isolates (collected in 2009 through 2013) from 127 inpatient and outpatient facilities, to assess antibiotic resistance among Veterans Affairs health care system patients using Clinical and Laboratory Standards Institute and Centers for Disease Control and Prevention National Healthcare Safety Network definitions or guidance. Rates of resistance to amoxicillin or ampicillin\/\u03b2-lactamase inhibitors were approximately 40% and rates of resistance to fluoroquinolones and trimethoprim-sulfamethoxazole approached 30%. Rates of resistance to nitrofurantoin, antipseudomonal penicillin\/\u03b2-lactamase inhibitors, and carbapenems remained less than 10%. The percentage of isolates that were considered multidrug resistant varied (4% to 37%), depending on the definitions used.\n          <\/jats:p>","DOI":"10.1128\/aac.02236-16","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T01:55:24Z","timestamp":1487037324000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":40,"title":["Antimicrobial Resistance of Escherichia coli Urinary Isolates in the Veterans Affairs Health Care System"],"prefix":"10.1128","volume":"61","author":[{"given":"Haley J.","family":"Morrill","sequence":"first","affiliation":[{"name":"Veterans Affairs Medical Center, Infectious Diseases Research Program, Providence, Rhode Island, USA"},{"name":"Veterans Affairs Medical Center, Center of Innovation in Long Term Services and Supports, Providence, Rhode Island, USA"},{"name":"University of Rhode Island, Department of Pharmacy Practice, College of Pharmacy, Kingston, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob B.","family":"Morton","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, Infectious Diseases Research Program, Providence, Rhode Island, USA"},{"name":"University of Rhode Island, Department of Pharmacy Practice, College of Pharmacy, Kingston, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling R.","family":"Caffrey","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, Infectious Diseases Research Program, Providence, Rhode Island, USA"},{"name":"Veterans Affairs Medical Center, Center of Innovation in Long Term Services and Supports, Providence, Rhode Island, USA"},{"name":"University of Rhode Island, Department of Pharmacy Practice, College of Pharmacy, Kingston, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, Center of Innovation in Long Term Services and Supports, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dosa","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, Center of Innovation in Long Term Services and Supports, Providence, Rhode Island, USA"},{"name":"Center for Gerontology and Health Care Research, Brown University School of Public Health, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard A.","family":"Mermel","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, Center of Innovation in Long Term Services and Supports, Providence, Rhode Island, USA"},{"name":"Department of Epidemiology and Infection Control, Rhode Island Hospital, Providence, Rhode Island, USA"},{"name":"Warren Alpert Medical School of Brown University, Department of Medicine, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"LaPlante","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center, Infectious Diseases Research Program, Providence, Rhode Island, USA"},{"name":"Veterans Affairs Medical Center, Center of Innovation in Long Term Services and Supports, Providence, Rhode Island, USA"},{"name":"University of Rhode Island, Department of Pharmacy Practice, College of Pharmacy, Kingston, Rhode Island, USA"},{"name":"Warren Alpert Medical School of Brown University, Department of Medicine, Providence, Rhode Island, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/650482"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/511864"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1198-743x.2001.00239.x"},{"key":"e_1_3_2_6_2","volume-title":"Analysis and presentation of cumulative antimicrobial susceptibility test data; approved guideline\u20144th ed","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. Analysis and presentation of cumulative antimicrobial susceptibility test data; approved guideline\u20144th ed. CLSI document M39-A4. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_3_2_8_2","volume-title":"Department of Veterans Affairs statistics at a glance (updated 06\/30\/2015.)","author":"National Center for Veterans Analysis and Statistics","unstructured":"National Center for Veterans Analysis and Statistics. Department of Veterans Affairs statistics at a glance (updated 06\/30\/2015.). U.S. Department of Veterans Affairs, Washington, DC. http:\/\/www.va.gov\/vetdata\/docs\/Quickfacts\/Stats_at_a_glance_08_27_15.pdf."},{"key":"e_1_3_2_9_2","volume-title":"Antimicrobial use and resistance (AUR) module","author":"Centers for Disease Control and Prevention","year":"2014","unstructured":"Centers for Disease Control and Prevention. 2014. Antimicrobial use and resistance (AUR) module. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/nhsn\/PDFs\/pscManual\/11pscAURcurrent.pdf."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/321893"},{"key":"e_1_3_2_11_2","volume-title":"CLSI document M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_12_2","volume-title":"Antibiotic resistance patient safety atlas: phenotype definitions","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention. 2016. Antibiotic resistance patient safety atlas: phenotype definitions. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/gis.cdc.gov\/grasp\/PSA\/Downloads\/ARPatientSafetyAtlas-PhenotypeDefinitions.pdf."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.04.022"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02505-15"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06060-11"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02897-15"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02236-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02236-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:55:03Z","timestamp":1645476903000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02236-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1128\/AAC.02236-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02236-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2016-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02236-16"}}